Jim Simons’s Belite Bio BLTE Stock Holding History

Jim Simons’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.29M	Buy	+52,000	New	+$8.74M	0.01%	1069
2025 Q4	–	Sell	-2,812	Closed	-$208K	–	3261
2025 Q3	$208K	Sell	2,812 -1,488	-35%	-$97.7K	﹤0.01%	3125
2025 Q2	$248K	Buy	+4,300	New	+$262K	﹤0.01%	3099
2024 Q1	–	Sell	-4,900	Closed	-$224K	–	3712
2023 Q4	$224K	Buy	+4,900	New	+$188K	﹤0.01%	3093

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jim Simons's BLTE Position: Q1 2026 in Review

Jim Simons opened a new position in Belite Bio (BLTE) in Q1 2026: 52,000 shares worth $8.29M. The stake represents 0.01% of the portfolio and ranks #1069 among its holdings. This is a return to the name: Jim Simons previously reported a position in BLTE as recently as Q3 2025.

Jim Simons first reported a position in BLTE in Q4 2023 and has held it in 4 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

Jim Simons held 52,000 shares of Belite Bio worth $8.29M as of Q1 2026.
Belite Bio was a new Jim Simons position in Q1 2026.
Belite Bio made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1069 holding.
Jim Simons first reported a position in Belite Bio in Q4 2023 and has held it in 4 quarters since.
75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.